Article Text
Statistics from Altmetric.com
Description
A girl in her teens presented to our rheumatology service for a bruising eye, with sudden onset of whitish layer in front part of the left eye (figure 1). She was cared for ANA-positive and HLAB27-positive psoriatic arthritis associated with recurrent iridocyclitis. Two days before, despite immunosuppressive treatment with adalimumab, she had presented a relapse of iridocyclitis in the left eye, therefore, a treatment with oral corticosteroids and mydriatic drops had been started.
At the visit, a hypopyon was evident and the slit-lamp examination showed cells 4+, Tyndall 2+. Thus, the treatment was intensified with an intravenous bolus of methylprednisolone (5 mg/kg), carrying on oral corticosteroid therapy. After 1 week, her conditions consistently improved and the steroid therapy was gradually decreased.
Hypopyon is an inflammatory condition characterised by an exudate rich in white blood cells in the anterior chamber of the eye. It has diagnostic value, because it tends to occur in association with specific conditions rather than as a general ocular inflammation.1 This condition has been rarely described in children, and it has been reported in a few cases of juvenile idiopathic arthritis with uveitis.2 3 HLAB27 is considered a risk factor for hypopyon in patients with iridocyclitis. Fortunately, hypopyon does not appear to be associated with poor ophthalmological outcomes.3 This case highlights that children with iridocyclitis require a close follow-up and that urgent clinical evaluation is needed in the presence of symptomatic iridocyclitis to allow effective treatment with high-dose glucocorticoids.
Learning points
Systemic corticosteroid therapy should be considered whenever there is no response to topical treatment.
Hypopyon uveitis could be an ophthalmic finding associated with psoriasic arthritis.
Ethics statements
Patient consent for publication
Footnotes
Contributors CT and FB wrote the first draft of this article. SP and AT reviewed the article before submission.
Funding This study was funded by Ministero della Salute (RC 23/2022).
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.